<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39460489</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1346-8138</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>26</Day></PubDate></JournalIssue><Title>The Journal of dermatology</Title><ISOAbbreviation>J Dermatol</ISOAbbreviation></Journal><ArticleTitle>First reported case of thymoma-associated multiorgan autoimmunity induced by COVID-19.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/1346-8138.17519</ELocationID><Abstract><AbstractText>Thymoma-associated multiorgan autoimmunity (TAMA) presents with skin symptoms similar to those of graft-versus-host disease (GVHD), liver dysfunction, and enteritis, in the absence of a history of hematopoietic stem cell or bone marrow transplantation. TAMA is a type of paraneoplastic syndrome associated with thymoma. Its etiology is unclear but is thought to be a result of breakdown of immune tolerance. Histopathologically, TAMA is characterized by epidermal acanthosis with parakeratosis, individual cell keratinization, liquefaction degeneration, and intraepidermal infiltration of CD8-positive lymphocytes. A 64-year-old female patient with a history of myasthenia gravis and thymoma treated with prednisolone (10 mg/day) and cyclosporine (150 mg/day) experienced erythema on her trunk after coronavirus disease 2019 (COVID-19) onset. A psoriatic drug eruption was suspected and the possible causative drug was discontinued, but the skin rash failed to improve. A skin biopsy demonstrated GVHD-like histopathological findings. Diarrhea, abdominal pain, and duodenal perforation occurred concurrently, leading to the diagnosis of TAMA. Thereafter, the patient continued prednisolone and cyclosporine in the same doses as the TAMA treatment and added topical steroids. During the disease course, candida fungemia and cytomegalovirus infection developed, resulting in the patient's death. The TAMA was considered to have been caused by the release of inflammatory cytokines, autoreactive T cell activation, and regulatory T cell dysfunction induced by COVID-19.</AbstractText><CopyrightInformation>© 2024 The Author(s). The Journal of Dermatology published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Dermatological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hyobu</LastName><ForeName>Rie</ForeName><Initials>R</Initials><Identifier Source="ORCID">0009-0008-1960-3326</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Tokyo Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Miho</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Tokyo Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maeda</LastName><ForeName>Tatsuo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Tokyo Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujimori</LastName><ForeName>Kazuki</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Tokyo Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimai</LastName><ForeName>Yukako</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Tokyo Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naito</LastName><ForeName>Makiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokyo Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masuda</LastName><ForeName>Masayuki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokyo Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohira</LastName><ForeName>Tatsuo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Surgery, Tokyo Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikeda</LastName><ForeName>Norihiko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Surgery, Tokyo Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okubo</LastName><ForeName>Yukari</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-9526-1259</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Tokyo Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harada</LastName><ForeName>Kazutoshi</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-9059-4097</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Tokyo Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Dermatol</MedlineTA><NlmUniqueID>7600545</NlmUniqueID><ISSNLinking>0385-2407</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19</Keyword><Keyword MajorTopicYN="N">alopecia</Keyword><Keyword MajorTopicYN="N">graft‐versus‐host disease</Keyword><Keyword MajorTopicYN="N">myasthenia gravis</Keyword><Keyword MajorTopicYN="N">thymoma</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>3</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460489</ArticleId><ArticleId IdType="doi">10.1111/1346-8138.17519</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Kornacki S, Hansen FC III, Lazenby A. Graft‐versus‐host‐like colitis associated with malignant thymoma. Am J Surg Pathol. 1995;19:224–228.</Citation></Reference><Reference><Citation>Wadhera A, Maverakis E, Mitsiades N, Lara PN, Fung MA, Lynch PJ. Thymoma‐associated multiorgan autoimmunity: a graft‐versus‐host‐like disease. J Am Acad Dermatol. 2007;57:683–689.</Citation></Reference><Reference><Citation>Song G, Yoon HY, Yee J, Kim MG, Gwak HS. Antihypertensive drug use and psoriasis: a systematic review, meta‐ and network meta‐analysis. Br J Clin Pharmacol. 2022;88:933–941.</Citation></Reference><Reference><Citation>Hanafusa T, Azukizawa H, Kitaba S, Murota H, Umegaki N, Terao M, et al. Diminished regulatory T cells in cutaneous lesions of thymoma‐associated multi‐organ autoimmunity: a newly described paraneoplastic autoimmune disorder with fatal clinical course. Clin Exp Immunol. 2011;166:164–170.</Citation></Reference><Reference><Citation>Shiba K, Fujita Y, Miyazawa H, Muramatsu K, Watanabe M, Nishimura M, et al. Thymoma‐associated multi‐organ autoimmunity: two cases and a review of the literature. J Eur Acad Dermatol Venereol. 2017;31:e324–6.</Citation></Reference><Reference><Citation>Kamada N, Hatamochi A, Shinkai H. Alopecia areata associated with myasthenia gravis and thymoma: a case of alopecia with marked improvement following thymectomy and high‐level prednisolone administration. J Dermatol. 1997;24:769–772.</Citation></Reference><Reference><Citation>Offerhaus GJ, Schipper ME, Lazenby AJ, Montgomery E, Morsink FH, Bende RJ, et al. Graft‐versus‐hostlike disease complicating thymoma: lack of AIRE expression as a cause of non‐hereditary autoimmunity? Immunol Lett. 2007;114:31–37.</Citation></Reference><Reference><Citation>Wang H, Wang Z, Cao W, Wu Q, Yuan Y, Zhang X. Regulatory T cells in COVID‐19. Aging Dis. 2021;12:1545–1553.</Citation></Reference><Reference><Citation>Peng K, Li X, Yang D, Chan SCW, Zhou J, Wan EYF, et al. Risk of autoimmune diseases following COVID‐19 and the potential protective effect from vaccination: a population‐based cohort study. eClinicalMedicine. 2023;63:102154.</Citation></Reference><Reference><Citation>Syed U, Subramanian A, Wraith DC, Lord JM, McGee K, Ghokale K, et al. Incidence of immune‐mediated inflammatory diseases following COVID‐19: a matched cohort study in UK primary care. BMC Med. 2023;21:363.</Citation></Reference><Reference><Citation>Henden AS, Hill GR. Cytokines in graft‐versus‐host disease. J Immunol. 2015;194:4604–4612.</Citation></Reference><Reference><Citation>Florenzo B, Martin S, Saavedra A. Reactivated chronic graft‐versus‐host disease following SARS‐CoV‐2 infection. J Am Acad Dermatol Case Rep. 2022;26:76–78.</Citation></Reference><Reference><Citation>Ozawa N, Yamazaki K, Kushima R. Graft‐versus‐host disease‐like reactions in the gastrointestinal tract in a patient with SARS‐CoV‐2 infection. Dig Endosc. 2021;33:876–877.</Citation></Reference><Reference><Citation>Mizutani H, Suehiro M, Sakurai T, Masuda K, Katoh N. Case of thymoma‐associated multi‐organ autoimmunity following herpes zoster. J Dermatol. 2017;44:e85–6.</Citation></Reference><Reference><Citation>Kitamura K, Asada H, Iida H, Fukumoto T, Kobayashi N, Niizeki H, et al. Relationship among human herpesvirus6 reactivation, serum interleukin 10 levels, and rash/graft‐versus‐host disease after allogeneic stem cell transplantation. J Am Acad Dermatol. 2008;58:802–809.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>